Athira Pharma, Inc. — Director's Dealing 2022

Jan 20, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-01-18

Reporting Person: Lenington Rachel (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-18	Stock Option (Right to Buy)	$10.64	A	180000	Acquired	2032-01-17	Common Stock (180000)	Direct

Footnotes

F1: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.